Mark R. Litzow, MD (IMAGE)
Caption
"Our study shows that adding blinatumomab to consolidation chemotherapy keeps patients in remission and improves their survival. Based on what we found, this approach is the new standard of care for B-cell precursor acute lymphoblastic leukemia patients who achieve an MRD-negative remission after initial chemotherapy," said lead investigator Mark R. Litzow, MD (pictured), a Professor of Medicine (now retired) at the Mayo Clinic.
Credit
ECOG-ACRIN
Usage Restrictions
No restrictions.
License
Public Domain